Who are ART 44's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doravirine (DOR), Emtricitabine and Tenofovir, Emtricitabine/tenofovir disoproxil fumarate, Emtricitabine / Tenofovir Disoproxil Oral Tablet, Etravirine (ETR), Emtricitabine / Tenofovir Disoproxil Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/art-44.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ART 44 — Competitive Intelligence Brief

ART 44 (ART 44) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor. Area: Infectious Diseases.

phase 3 Non-nucleoside reverse transcriptase inhibitor HIV-1 reverse transcriptase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

ART 44 (ART 44) — Laboratoires NEGMA. ART 44 is an antiretroviral drug used to treat HIV-1 infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ART 44 TARGET	ART 44	Laboratoires NEGMA	phase 3	Non-nucleoside reverse transcriptase inhibitor	HIV-1 reverse transcriptase
Doravirine (DOR)	Doravirine (DOR)	Walter K. Kraft	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine and Tenofovir	Emtricitabine and Tenofovir	Puerto Rico Community Network for Clinical Research on AIDS	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Oral Tablet	Emtricitabine / Tenofovir Disoproxil Oral Tablet	University of Chicago	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Etravirine (ETR)	Etravirine (ETR)	ViiV Healthcare	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV-1 reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor class)

Laboratoires NEGMA · 2 drugs in this class
IRCCS Eugenio Medea · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ART 44 — Competitive Intelligence Brief. https://druglandscape.com/ci/art-44. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab